Reduce Cost to Closure and Minimize Graft Wastage with EpiFix®


Reduce Cost to Closure and Minimize Graft Wastage with EpiFix®

DID YOU KNOW?
77% of DFUs and 67% of VLUs have an area of less than or equal to 5 sq cm1

EpiFix® dehydrated Human Amnion/Chorion Membrane allograft provides a scaffold and growth factors for cellular ingrowth, and it reduces inflammation and scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix® minimizes graft waste and overall treatment costs to heal wounds. To that end, MiMedx Supports the CMS 2014 Hospital Outpatient Prospective Payment System Proposed Rule for Skin Substitutes.

Click here to read a white paper on the proposed CMS reimbursement changes, the impact on chronic wound care and new skin substitute product options to help reduce wastage.

While MiMedx is supportive of CMS and its goal to minimize cost and waste in the skin substitute category for hospital outpatient services, the Company has proposed an alternative 4-tiered system for payment based on wound size/complications.

Additional CMS wastage data2:

  • $94 million of the $101 million CMS paid was used for only Apligraf® and Dermagraft®
  • With multiple size appropriate grafts, EpiFix®represents cost savings in the treatment of acute and chronic wounds. 

 

 

1 - James R. Wilcox, RN; Marissa J. Carter, PhD, MA; Scott Covington, MD. Frequency of Debridements and Time to Heal A Retrospective Cohort Study of 312,744 Wounds. JAMA Dermatol. doi:10.1001/jamadermatol.2013.4960 published online July 24, 2013; 2 - Calculated from 2011 CMS Medicare data